IRS Tells Tax Court AbbVie's $1.6B Break Fee Is A Capital Loss
The Internal Revenue Service correctly reclassified AbbVie's $1.6 billion break fee to an Irish biotechnology company as a capital loss, the agency told the U.S. Tax Court, arguing that the failed...To view the full article, register now.
Already a subscriber? Click here to view full article